Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure.

Fecha de publicación: 20/01/2025 Fecha Ahead of Print: 01/01/2025

Autores de IIS La Fe

Estefanía Tarazón Melguizo

Autor
Esther Roselló Lletí

Autor
Manuel Portoles Sanz

Autor
Francisca Lago Paz

Autor

Participantes ajenos a IIS La Fe

Anido-Varela, Laura
Aragon-Herrera, Alana
Gonzalez-Maestro, Adrian
Bellas, Carlos Tilves
Sole-Gonzalez, Eduard
Martinez-Selles, Manuel
Guerra-Ramos, Jose Maria
Carrasquer, Anna
Moran-Fernandez, Laura
Garcia-Vega, David
Seoane-Blanco, Ana
Moure-Gonzalez, Maria
Seijas-Amigo, Jose
Rodriguez-Penas, Diego
Garcia-Seara, Javier
Morana-Fernandez, Sandra
Vazquez-Abuin, Xocas
Eiras, Sonia
Agra, Rosa M
Alvarez, Ezequiel
Gonzalez-Juanatey, Jose R
Feijoo-Bandin, Sandra
REDINSCOR III registry

Grupos

Grupo de Investigación Clínica y Traslacional en Cardiología

Investigador Principal

Esther Roselló Lletí

Abstract

BACKGROUND AND AIMS: Meteorin-like protein (Metrnl) has been recently suggested as a new adipokine with protective cardiovascular effects. Its circulating levels in patients seem to be associated with heart failure (HF), although with contradictory results. Our aim was to ascertain whether this adipokine could estimate the prognosis of HF in de novo HF (DNHF) patients. METHODS: Metrnl plasma levels of 400 patients hospitalized with DNHF (55% of patients with HF with reduced ejection fraction, 17.3% HF with mid-range ejection fraction, 27.8% HF with preserved ejection fraction) were measured by enzyme-linked immunosorbent assay. We performed both sex-pooled and sex-specific analyses. A 12-month follow-up was conducted, during which clinical outcomes such as all-cause mortality, cardiovascular death and re-hospitalization due to HF were collected. RESULTS: After a 12-month follow up, higher plasma Metrnl levels were associated with an increased risk for all-cause death and cardiovascular death after adjusting by sex, age, LVEF, hypertension, diabetes, ischemic aetiology, chronic renal failure, NT-proBNP and troponin (hazard ratio [HR]=1.003, 95% confidence interval [CI]=1.000-1.005; p-value<.05 and HR=1.004, 95% CI=1.001-1.007, p-value<.05, respectively). In line with this, DNHF patients with increased levels of circulating Metrnl had a higher number of occurrences of cardiovascular events. Regarding Metrnl associations with parameters implicated in the development and progression of HF, we found that Metrnl circulating levels were positively correlated with age (r=.322, p-value<.0001), NT-proBNP (r=.281, p-value<.0001) and with the renal dysfunction markers urea (r=.322, p-value<.0001) and creatinine (r=.353, p-value<.0001) and higher in women than men (473.7 [385.9-594.0] pg/mL vs. 428.7 [349.1-561.3] pg/mL, p-value<.006). Finally, concerning the subtype of HF, Metrnl plasma levels were higher in HF with preserved ejection fraction. CONCLUSION: Patients with higher Metrnl levels have a worse prognosis in DNHF. Our results reinforce the association of Metrnl plasma levels with HF progression and outcomes.

Datos de la publicación

ISSN/ISSNe:: 0014-2972, 1365-2362
Tipo:: Article
Páginas:: 14380-14380
DOI:: 10.1111/eci.14380
Factor de Impacto:: 1,229 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

- Captures
  Readers: 1
see details

Filiaciones

Filiaciones no disponibles

Campos de estudio

Proyectos asociados

REDINSCOR

RD06/0003/1001 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2008

APOPTOSIS EN EL RECHAZO AGUDO DEL INJERTO CARDIACO ALOGENICO

Investigador Principal: LUIS ALMENAR BONET

AP-196/10 . 2010

CINETICA DEL TRANSPORTE NUCLEO-CITOPLASMATICO DE LOS CARDIOMIOCITOS HUMANOS EN LA INSUFICIENCIA CARDIACA. ANALISIS CELULAR Y DE EXPRESION GENICA

PI10/00275 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010

REGISTRO MULTICÉNTRICO DE PACIENTES HOSPITALIZADOS POR INSUFICIENCIA CARDÍACA AGUDA (REDINSCOR II).

RD12/0042/0003 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

TRANSPORTE NÚCLEO CITOPLASMA Y CAMBIOS DE EXPRESIÓN GÉNICA EN LA INSUFICIENCIA CARDIACA. PUESTA EN MARCHA DE UNA NUEVA ESTRATEGIA TERAPÉUTICA.

Investigador Principal: JOSE MIGUEL RIVERA OTERO

PI13/00100 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014

ESTANCIA DE CONTRATADOS PREDOCTORALES EN CENTROS FUERA DE LA COMUNIDAD VALENCIANA

BEFPI/2014 . 2014

SEGUIMIENTO DE PACIENTES SOMETIDOS A TRASPLANTE CARDIACO. ESTUDIO DE MARCADORES DE RECHAZO IMPLICADOS EN EL TRANSPORTE NÚCLEO-CITOPLASMA.

Investigador Principal: ESTHER ROSELLÓ LLETÍ

PI14/01506 . INSTITUTO DE SALUD CARLOS III . 2015

PAPEL PROTECTOR DE BH4 EN LA DISFUNCIÓN VENTRICULAR. UNA PROMETEDORA ESTRATEGIA TERAPÉUTICA EN LA

Investigador Principal: ESTHER ROSELLÓ LLETÍ

CAS14/00111 . MINISTERIO DE EDUCACION, CULTURA Y DEPORTE; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014